盐酸氮卓斯汀联合糠酸莫米松喷鼻治疗持续性变应性鼻炎的临床疗效分析

Clinical efficacy of azelastine hydrochloride combined with mometasone furoate nasal spray in the treatment of persistent allergic rhinitis

目的:观察盐酸氮卓斯汀联合糠酸莫米松喷鼻治疗持续性变应性鼻炎的临床疗效。方法:将147例持续性变应性鼻炎患者随机均等分成3组,A组单独采用盐酸氮卓斯汀喷鼻,B组单独采用糠酸莫米松喷鼻,C组采用氮卓斯汀和糠酸莫米松联合喷鼻,根据患者主观感受及鼻部症状,评价各组临床疗效及不良反应。结果:治疗后,A组、B组、C组有效率分别为71.43%、69.39%、85.71%,组间差异具统计学意义(χ^2=21.16,P=0.03);联合用药组(C组)有效率显著高于单独用药组(A组、B组),差异具统计学意义(P <0.05);A组与B组相比,组间差异无统计学意义(P> 0.05)。三组均未发生严重不良反应。结论:盐酸氮卓斯汀联合糠酸莫米松喷鼻治疗能明显改善持续性变应性鼻炎症状,临床疗效好,值得推广。

Objective: To investigate the clinical efficacy of azelastine hydrochloride combined with mometasone furoate nasal spray in the treatment of persistent allergic rhinitis. Methods: A total of 147 patients with persistent allergic rhinitis were randomly divided into three groups: group A(receiving azelastine hydrochloride nasal spray), group B(receiving mometasone furoate nasal spray), and group C(receiving azelastine hydrochloride combined with mometasone furoate nasal spray). The subjective feeling and nasal symptoms of patients were observed to evaluate the clinical efficacy and adverse reaction in each group. Results: After treatment, the response rates of group A, group B, and group C were 71.43%, 69.39%, and 85.71%, respectively;there was a significant difference between the three groups(χ^2= 21.16, P = 0.03). Group C had a significantly higher response rate than group A and group B(P < 0.05), but there was no significant difference between group A and group B(P > 0.05). No serious adverse reactions occurred in the three groups. Conclusion: Azelastine hydrochloride and mometasone furoate nasal spray can significantly relieve the symptoms of persistent allergic rhinitis, with good clinical effects. Therefore, it holds promise for application in clinical practice.